Paper21692829
Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.
Valenzuela B and 4 others. Br J Clin Pharmacol, 2011. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report. Papers, record 21692829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21692829
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Citrus paradisi | Major topic |
| Food-Drug Interactions | Major topic |
| Taxoids | Major topic |
| Beverages | |
| Carcinoma, Squamous Cell | |
| Cytochrome P-450 CYP3A | |
| Cytochrome P-450 CYP3A Inhibitors | |
| Docetaxel | |
| Esophageal Neoplasms | |
| Female | |
| Humans | |
| Middle Aged |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10778948 | The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10778948 | PubMed |
| 2 | 20573082 | Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. | Br J Clin Pharmacol | 2010 | https://conductscience.org/library/papers/20573082 | PubMed |
| 3 | 11768292 | Ways to fit a PK model with some data below the quantification limit. | J Pharmacokinet Pharmacodyn | 2001 | https://conductscience.org/library/papers/11768292 | PubMed |
| 4 | 9654116 | Evaluation of the linearity of docetaxel pharmacokinetics. | Cancer Chemother Pharmacol | 1998 | https://conductscience.org/library/papers/9654116 | PubMed |
| 5 | 20430905 | Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. | Ann Oncol | 2010 | https://conductscience.org/library/papers/20430905 | PubMed |
| 6 | 9440742 | Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9440742 | PubMed |
| 7 | 15116057 | Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. | Clin Pharmacol Ther | 2004 | https://conductscience.org/library/papers/15116057 | PubMed |
| 8 | 12953340 | Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. | J Clin Pharmacol | 2003 | https://conductscience.org/library/papers/12953340 | PubMed |
| 9 | 9815840 | Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. | Clin Cancer Res | 1997 | https://conductscience.org/library/papers/9815840 | PubMed |
| 10 | 16628131 | Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. | Ther Drug Monit | 2006 | https://conductscience.org/library/papers/16628131 | PubMed |
| 11 | 7907950 | Pharmacokinetics and metabolism of Taxotere (docetaxel). | Cancer Surv | 1993 | https://conductscience.org/library/papers/7907950 | PubMed |
| 12 | 15041715 | Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15041715 | PubMed |
| 13 | 16509758 | Clinical pharmacokinetics of docetaxel : recent developments. | Clin Pharmacokinet | 2006 | https://conductscience.org/library/papers/16509758 | PubMed |
| 14 | 17956601 | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. | BMC Cancer | 2007 | https://conductscience.org/library/papers/17956601 | PubMed |
| 15 | 21224369 | Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21224369 | PubMed |
| 16 | 8875345 | A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. | J Pharmacokinet Biopharm | 1996 | https://conductscience.org/library/papers/8875345 | PubMed |
| 17 | 11180028 | Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. | Clin Pharmacol Ther | 2000 | https://conductscience.org/library/papers/11180028 | PubMed |
| 18 | 19924122 | Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/19924122 | PubMed |
| 19 | 15585753 | Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15585753 | PubMed |
| 20 | 19920203 | Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. | Cancer Res | 2009 | https://conductscience.org/library/papers/19920203 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41002089 | [Breast cancer survivor program: follow-up, rehabilitation, psycho-oncology, palliative care]. | Magy Onkol | 2025 | https://conductscience.org/library/papers/41002089 | PubMed |
| 40507996 | Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40507996 | PubMed |
| 39386271 | Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model. | Transl Clin Pharmacol | 2024 | https://conductscience.org/library/papers/39386271 | PubMed |
| 36493603 | Cytochrome P-450-mediated herb and food-drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study. | ESMO Open | 2022 | https://conductscience.org/library/papers/36493603 | PubMed |
| 35568834 | A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35568834 | PubMed |
| 31850232 | Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings. | Front Oncol | 2019 | https://conductscience.org/library/papers/31850232 | PubMed |
| 29667038 | Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. | Clin Pharmacokinet | 2018 | https://conductscience.org/library/papers/29667038 | PubMed |
| 28814868 | Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. | Int J Nanomedicine | 2017 | https://conductscience.org/library/papers/28814868 | PubMed |
| 28261555 | Food and Drug Interactions. | J Lifestyle Med | 2017 | https://conductscience.org/library/papers/28261555 | PubMed |
| 23673492 | Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence. | Eur J Drug Metab Pharmacokinet | 2013 | https://conductscience.org/library/papers/23673492 | PubMed |
| 22884524 | Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. | Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22884524 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21692829
GET https://conductscience.org/api/papers/v1/21692829/references?page=2